Rates of clinical progression according to biological Alzheimer's disease stages
Alzheimer's & Dementia · 2025-09 · 21 (9)
DOI: 10.1002/alz.70624 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 15.09.2025. Verfasst von Lydia Trudel und 23 weiteren Autor:innen. Beteiligte Einrichtung: Translational Neuroimaging Laboratory Department of Neurology and Neurosurgery, McConnell Brain Imaging Centre, Montreal Neurological Institute, McGi…. Hauptthemen laut MEDLINE: Disease Progression, Alzheimer Disease, Cognitive Dysfunction. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIA NIH HHS, Alzheimer's Association, Weston Brain Institute.
Themen: Demenz
Abstract (Originalsprache)
INTRODUCTION Predicting the rate of cognitive decline and the likelihood of progression to dementia remains a critical unmet need in clinical settings. METHODS We assessed progression to mild cognitive impairment (MCI) and all‐cause dementia in 492 individuals from the TRIAD, ADNI, and HABS‐HD cohorts followed for an average of 2.49 years. Amyloid‐positive participants were staged according to the Alzheimer's Association biological staging framework (A+T 2 ‐/A+T 2MTL +/A+T 2MOD +/A+T 2HIGH +). RESULTS Cognitively unimpaired (CU) individuals in the A+T 2MTL +, A+T 2MOD +, and A+T 2HIGH + biological Alzheimer's disease (AD) stages were at significantly higher risk of clinical progression compared to non‐AD CU individuals. In individuals with MCI, advanced tau stage was associated with an 83% likelihood of developing dementia over 4 years. Biological AD staging demonstrated superior accuracy in predicting clinical progression compared to amyloid‐PET (positron emission tomography) status, tau‐PET status, and demographic information. All tau‐PET‐positive individuals showed a significantly faster rate of cognitive decline than non‐AD controls, with the A+T 2HIGH + stage showing the steepest rate of decline ( p < 0.001). DISCUSSION Our results highlight the prognostic value of biological AD staging. Highlights Cognitively unimpaired (CU) individuals in all tau‐PET (positron emission tomography)–positive biological Alzheimer's disease (AD) stages were at significantly higher risk of clinical progression compared to individuals without AD. In individuals with mild cognitive impairment (MCI), only the A+T 2HIGH + stage reached a point where 50% of individuals had progressed to all‐cause dementia, after 2.36 years. Biological AD staging demonstrated superior accuracy in predicting clinical progression to dementia compared to other PET biomarkers and demographic information. All tau‐PET‐positive individuals showed a significantly faster rate of cognitive decline than individuals without AD, with the A+T 2HIGH + stage showing the steepest rate of decline.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Translational Neuroimaging Laboratory Department of Neurology and Neurosurgery, McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada.
- McGill University Research Centre for Studies in Aging, Douglas Hospital Research Centre - Centre intégré universitaire de santé et services sociaux de l'Ouest-de-l'Île-de-Montréal, Montreal, Québec, Canada.
- PET Unit, McConnell Brain Imaging Centre, Montreal, Quebec, Canada.
- Mark and Mary Stevens Neuroimaging and Informatics Institute Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
- Institute for Translational Research, University of North Texas Health Science Center, Fort Worth, Texas, USA.
- Department of Family Medicine, University of North Texas Health Science Center, Fort Worth, Texas, USA.
ORCID-Profile: Lydia Trudel
Förderung
- NIA NIH HHS
- Alzheimer's Association
- Weston Brain Institute
- Consortium canadien en neurodégénérescence associée au vieillissement
- CIHR
- Fondation Brain Canada
- Fonds de Recherche du Québec - Santé
- Canadian Institutes of Health Research
Zitieren
APA
Trudel, L., Therriault, J., Macedo, A. C., Servaes, S., Hosseini, S. A., Bezgin, G., Rahmouni, N., Chan, T., Fernandez-Arias, J., Aumont, É., Wang, Y. T., Zheng, Y., Hall, B., Hopewell, R., Hsiao, C. H., Toga, A. W., Braskie, M. N., Meeker, K. L., Soucy, J. P., …, & Rosa-Neto, P. (2025). Rates of clinical progression according to biological Alzheimer's disease stages. Alzheimer's & Dementia, 21(9). https://doi.org/10.1002/alz.70624
Vancouver
Trudel L, Therriault J, Macedo AC, Servaes S, Hosseini SA, Bezgin G, et al. Rates of clinical progression according to biological Alzheimer's disease stages. Alzheimer's & Dementia. 2025;21(9). doi:10.1002/alz.70624
BibTeX
@article{Trudel2025,
author = {Trudel, Lydia and Therriault, Joseph and Macedo, Arthur C and Servaes, Stijn and Hosseini, Seyyed Ali and Bezgin, Gleb and Rahmouni, Nesrine and Chan, Tevy and Fernandez-Arias, Jaime and Aumont, Étienne and Wang, Yi-Ting and Zheng, Yansheng and Hall, Brandon and Hopewell, Robert and Hsiao, Chris Hung-Hsin and Toga, Arthur W and Braskie, Meredith N and Meeker, Karin L and Soucy, Jean-Paul and Gauthier, Serge and Vitali, Paolo and O'Bryant, Sid E and Pascoal, Tharick A and Rosa-Neto, Pedro},
title = {Rates of clinical progression according to biological Alzheimer's disease stages},
journal = {Alzheimer's & Dementia},
year = {2025},
volume = {21},
number = {9},
doi = {10.1002/alz.70624}
}
EUVIMED